Patents by Inventor Robert McKay

Robert McKay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220363671
    Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.
    Type: Application
    Filed: September 16, 2020
    Publication date: November 17, 2022
    Inventors: Jake AXFORD, Rohan Eric John BECKWITH, Simone BONAZZI, Nicole BUSCHMANN, Artiom CERNIJENKO, Janetta DEWHURST, Aleem FAZAL, Matthew James HESSE, Lauren HOLDER, Viktor HORNAK, Hidetomo IMASE, Rama JAIN, Xianming JIN, John Ryan KERRIGAN, Julie LACHAL, Fupeng MA, Hasnain Ahmed MALIK, James R. MANNING, Daniel MCKAY, Robert Joseph MOREAU, Pierre NIMSGERN, Gary O'BRIEN, Anna VULPETTI, Ken YAMADA, Junping ZHAO
  • Patent number: 11417168
    Abstract: An overhead display assembly includes a display monitor coupled to a monitor tray. The monitor tray is positionable in an operational position and a maintenance position. A support stanchion has an anchoring part, a coupling part, and a stanchion body extending from the anchoring part to the coupling part. The anchoring part is coupleable to a fixed vertical or horizontal supporting structure. A counter-balanced hinging mechanism has one or more pivots upon which monitor tray is configured to rotate with respect to said support stanchion. A force producing device is configured to apply a variable amount of force to the monitor tray based upon a position of the display monitor, the variable amount of force being at least a force sufficient to maintain the monitor tray stationary in an intermediate position between the operational position and the maintenance position.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: August 16, 2022
    Assignee: ARISTOCRAT TECHNOLOGIES AUSTRALIA PTY LIMITED
    Inventors: Rena Schoonmaker, Bruce Urban, Matthew McKay, Noel Voloh, Robert Wand, Gary Strahinic
  • Publication number: 20170228726
    Abstract: A system may transmit a time-based token to the merchant device. The system may receive a second merchant session key, a customer session key, a customer ID, a customer device certificate, and a second transaction amount from a customer device. The system may further match the first merchant session key to the second merchant session key, and transmit the time-based token to the customer device in response to the first merchant session key matching the second merchant session key.
    Type: Application
    Filed: February 4, 2016
    Publication date: August 10, 2017
    Applicant: AMERICAN EXPRESS TRAVEL RELATED SERVICES COMPANY, INC.
    Inventors: Billy Bohanan, Brady Cullimore, Justin Flaishans, Dinesh Gudibandi, Sean Maize, Robert Mckay, ShahanasSalam NaduvilePurayil, Rakesh Pattanayak, Dan Sorensen, Andrew Sosnicki
  • Patent number: 9617540
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: April 11, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Patent number: 9447591
    Abstract: A tool for finishing an outside corner comprises a handle and a V-shaped blade coupled to the handle. The V-shaped blade has a pair of planar blade surfaces which each extend from a vertex thereof. A retaining mechanism releasably retains a sponge against the surfaces of the V-shaped blade.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: September 20, 2016
    Inventor: Robert McKay
  • Publication number: 20150344879
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: April 28, 2015
    Publication date: December 3, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Patent number: 9071974
    Abstract: Methods, systems, and software for mediating SMS messages, and especially type 0 SMS messages, in a wireless mobile communications device configured to send and receive data using a GSM protocol and including a subscriber identity module (“SIM”) including electronic hardware and computer software executed by the hardware such that the SIM is configured to send, receive, and process messages using a Short Message System (“SMS”) between the wireless mobile communications device and a communications network. One aspect includes a method for mediating SMS messages comprising: configuring electronic hardware on the wireless mobile communications device to implement a firewall on the wireless mobile communications device, the firewall configured to identify and optionally mediate infrastructure SMS messages.
    Type: Grant
    Filed: June 28, 2009
    Date of Patent: June 30, 2015
    Assignee: Oceans Edge, Inc.
    Inventors: Robert McKay, Sam Emara, Steve Hildner, Thomas Shanley, Wesley Driver, Jay Lukin, Terry Bahr, Tim Berzins, Mihaela Mihaylova, Nathan Klonoski
  • Publication number: 20150167323
    Abstract: A tool for finishing an outside corner comprises a handle and a V-shaped blade coupled to the handle. The V-shaped blade has a pair of planar blade surfaces which each extend from a vertex thereof. A retaining mechanism releasably retains a sponge against the planar blade surfaces V-shaped blade.
    Type: Application
    Filed: September 15, 2014
    Publication date: June 18, 2015
    Inventor: Robert McKay
  • Patent number: 9045754
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: June 2, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Patent number: 8969316
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: March 3, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Publication number: 20150057329
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 26, 2015
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay BHANOT, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Publication number: 20140357856
    Abstract: The present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3?-endo conformational geometry (3?-endo regions) or DNA like having southern or C2?-endo/O4?-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in multiple in vitro and in vivo assay systems and are useful, for example, for investigative and therapeutic purposes.
    Type: Application
    Filed: June 13, 2014
    Publication date: December 4, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Brett P. Monia, Madeline M. Butler, Robert McKay, Brenda F. Baker
  • Patent number: 8853178
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: October 7, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Lex M. Cowsert, Jacqueline R. Wyatt, Brett P. Monia, Madelline M. Butler, Robert McKay, Susan M. Freier, Kenneth W. Dobie
  • Publication number: 20140275207
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMW-PTPase in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, and hyperfattyacidemia. In some embodiments, the diabetes is type II diabetes by administration of antisense compounds targeted to LMW-PTPase.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Sanjay K. Pandey, Robert McKay, Sanjay Bhanot, Xing-Xian Yu
  • Patent number: 8791083
    Abstract: The present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3?-endo conformational geometry (3?-endo regions) or DNA like having southern or C2?-endo/O4?-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in multiple in vitro and in vivo assay systems and are useful, for example, for investigative and therapeutic purposes.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: July 29, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Madeline M. Butler, Robert McKay, Brenda F. Baker
  • Patent number: 8673871
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: March 18, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Patent number: 8642753
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: February 4, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Kenneth W. Dobie, Robert McKay, Sanjay Bhanot
  • Patent number: 8586554
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: November 19, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Patent number: D955836
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: June 28, 2022
    Inventor: Robert McKay
  • Patent number: D955924
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: June 28, 2022
    Assignee: Thor Tech, Inc.
    Inventors: James Jack Owen Devine, Dale Beever, Raymond McKay Featherstone, Bryan M. Fox, Dana Kim Gehman, Bradley J. Mitchell, Robert Owen Sanford, Bryan Thompson